KR00001
Seoul, South Korea
NCT Number: NCT06505746
Cancer in the bladder lining (urothelial cancer) can be treated in many ways. One way is to directly attack cancer cells. Enfortumab vedotin is a treatment that can do this. Another way is to help the body's immune system find and attack cancer cells. Avelumab is a treatment that can do this. Both treatments were recently approved in some countries.
Doctors have standard clinical practice guidelines to help them treat people with cancer. This study is about collecting information on how adults with urothelial cancer are treated in standard clinical practice. The people in this study will have locally advanced or metastatic urothelial cancer. Locally advanced means the cancer has spread to tissue close by.
Metastatic means the cancer has spread to other parts of the body.
The goal of this study is to learn how people with urothelial cancer receive medical care in clinics in South Korea and Saudi Arabia. The main goals are to learn more about the people receiving treatments, and the treatments they receive.
This study is about collecting information only. The individual's doctor decides on treatment, not the study sponsor (Astellas).
Information will be collected from the people's medical records. This will include 12 months before treatment starts, and during treatment. Also, doctors will answer questions in interviews and surveys about how they care for people with urothelial cancer.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Seoul, South Korea
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Physician sample:
Patient sample:
Exclusion criteria
No investigational drug will be administered to participants in this study.
Time frame: Day 1
Demographics of interest will be recorded.
Time frame: Day 1
Clinical characteristics of interest will be recorded.
Time frame: Day 1
Details of current and previous therapies received for LA/mUC will be recorded.
Time frame: Day 1
LA/mUC Healthcare resources will be recorded.
Time frame: Day 1
Tumor biomarker, genetic tests results and PD1/PD-L1 expression status will be recorded.
Time frame: Day 1
Tests and assessments used to diagnosis patient's LA/mUC will be recorded.
Astellas Pharma Singapore Pte. Ltd.
Industry
Adelphi Real World Metastatic Urothelial Cancer Disease Specific Programme: Study of Real-world Data to Evaluate Patient Characteristics, Treatment Pattern and Healthcare Resource Utilisation of Locally Advanced or Metastatic Urothelial Cancer (La/mUC) at First-line Setting Post Avelumab Reimbursement in South Korea and Saudi Arabia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03682068
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Birmingham, Alabama, United States
View Trial DetailsNCT06225596
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Denver, Colorado, United States
View Trial DetailsNCT07548476
Advanced Urothelial Cancer, Female Urogenital Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT04995419
Metastatic Urothelial Cancer
Beijing, China
View Trial Details